^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation

Excerpt:
...a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
DOI:
10.1097/CAD.0000000000000277